In conclusion, our results demonstrate that the novel non-thiazolidinedione PPAR-γ agonist LSN862 elicited neuroprotective properties associated with modulation of oxidative stress and inflammation that can be beneficial for early PD. Here, PPARG is linked to Parkinson disease.